表紙
市場調査レポート

過敏性腸症候群:世界の治験レビュー

Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015

発行 GlobalData 商品コード 242604
出版日 ページ情報 英文 292 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
過敏性腸症候群:世界の治験レビュー Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015
出版日: 2015年12月16日 ページ情報: 英文 292 Pages
概要

過敏性大腸症候群(IBS)は、慢性的な特発性胃腸障害です。一般的な症候は腹部のけいれんまたは痛み、ガス過多による下腹部の張り、排便習慣の変化などです。 過敏性大腸症候群は、痙性結腸、機能性腸疾患、粘液性大腸炎とも呼ばれています。

当レポートでは、に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、お届けします。

イントロダクション

  • 過敏性大腸症候群
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域
    • 主要国における治験件数; 中南米

G7諸国における治験件数: 過敏性大腸症候群治験件数の消化管疾患治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数: 過敏性大腸症候群治験件数の消化管疾患治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

未完了の治験 過敏性大腸症候群

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - 過敏性大腸症候群治療薬

有望な薬剤

  • 最新治験ニュース: 過敏性大腸症候群

治験のプロファイル

  • 代表的な企業の治験の概要
    • GlaxoSmithKline plc
    • Novartis AG
    • Actavis plc
    • アステラス製薬
    • Salix Pharmaceuticals Ltd.
    • Ironwood Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • 小野薬品工業
    • Almirall, S.A.
    • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Srl
  • 代表的な研究機関/病院の治験の概要
    • Mayo Clinic
    • University of North Carolina
    • University of Nottingham
    • Maastricht University Medical Center
    • Sahlgrenska University Hospital
    • Chinese University of Hong Kong
    • Cedars-Sinai Medical Center
    • Karolinska Institute
    • University of California, Los Angeles
    • Baylor College of Medicine

5大治験プロファイル

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3084CTIDB

GlobalData's clinical trial report, "Irritable Bowel Syndrome Global Clinical Trials Review, H2, 2015" provides an overview of Irritable Bowel Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Irritable Bowel Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Irritable Bowel Syndrome Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Irritable Bowel Syndrome
      • Nov 30, 2015: Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan
      • Nov 19, 2015: Synthetic Biologics to Host Microbiome Clinical Program Seminar in New York City
      • Nov 02, 2015: Ironwood and Allergan Initiate Phase IIb Clinical Trial of Linaclotide Colonic Release in Adults with Irritable Bowel Syndrome with Constipation
      • Oct 20, 2015: Synthetic Biologics' Novel Irritable Bowel Syndrome with Constipation Program Featured in American College of Gastroenterology Poster
      • Oct 19, 2015: Allergan to Present New Data for VIBERZI (eluxadoline) at the American College of Gastroenterology 2015 Annual Scientific Meeting
      • Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D
      • Oct 13, 2015: Ironwood Reports Positive Top-Line Results from Phase III Trial of 72 mcg Linaclotide in Adults with Chronic Idiopathic Constipation
      • Oct 08, 2015: Synthetic Biologics Initiates Second SYN-010 Phase 2 Clinical Trial Intended to Treat Irritable Bowel Syndrome with Constipation (IBS-C)
      • Oct 08, 2015: Ardelyx to Present Phase 2 Data for Tenapanor in IBS-C Patients at the 2015 American College of Gastroenterology Annual Meeting
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries, 2015*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*

List of Figures

  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top